Genomics raises $32.5M to develop genetic database technology for drug development
Boston-based drugmaker Vertex Pharmaceuticals leads the round and also enters partnership with UK firm to aid its own drug development efforts.
Boston-based drugmaker Vertex Pharmaceuticals leads the round and also enters partnership with UK firm to aid its own drug development efforts.
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.